Methods: Asthma was confirmed by lung function test according to the GINA guidelines in patients attending Allergy and Pulmonology Clinic, Bhagwan Mahavir Hospital and Research Centre, Hyderabad, India, a tertiary care centre, during 2013-2015. Serum arginase was analyzed using a biochemical assay, total IgE and cytokine levels by enzyme-linked immunosorbent assay and genotyping of ARG1 for single-nucleotide polymorphisms (SNPs) rs2781666 and rs60389358 using polymerase chain reactionrestriction fragment length polymorphism (PCR-RFLP) method.
Studies on animal models and human asthma cases revealed that the enzyme arginase plays an important role in airway hyperresponsiveness (AHR) [1] [2] [3] [4] [5] . Arginase probably suppresses the generation of nitric oxide (NO), a bronchodilator by limiting the availability of arginine to NO synthase 6 . Utilization of arginine by arginase leads to the production of ornithine, putrescine, proline and spermidine, which are involved in collagen synthesis, mucus production, cell proliferation and differentiation 1, 6 . Low generation of NO and increased arginase metabolites may lead to AHR and bronchoconstriction 7 .
Kochański et al 8 first reported elevated levels of arginase in the sputum of individuals with bronchial asthma; however, its relevance and significance were not established until 2003 when Zimmermann et al 1 identified high expression of novel candidate genes arginase I (ARG1), arginase II and cationic amino acid transporter-2 in two different murine models sensitized with two different allergens. Further studies in animal models such as guinea pig and mice using different allergens revealed an increase in the levels of arginase and its association with disease development [2] [3] [4] [5] . In the murine model, ARG1 gene expression was upregulated ten folds upon ovalbumin challenge and was downregulated with the treatment of a new drug, R142571, indicating the role of arginase in asthma pathogenesis 9 . Studies in human asthmatics further established the function of arginase in pathogenesis of asthma based on the high levels of arginase expressing cells in bronchoalveolar lavage fluid 1 and elevated levels of arginase in the sputum 8 and serum 7 . Although different groups correlated high levels of arginase with asthma 7,10,11 , there are limited reports substantiating the same from India.
Th2 cytokines, interleukin (IL)-4 and IL-13 play a crucial role in the inflammation of airway. Studies on animal models of asthma 1 and cell lines 12 demonstrated that these cytokines have significant effect on induction of ARG1. Wei et al 13 reported the induction of ARG1 by IL-13 and IL-4 mediated through cAMP and JAK/STAT6 pathway in the rat aortic smooth muscle cells. In the murine model for asthma, Yang et al 14 demonstrated that IL-13-induced AHR was attenuated by the inhibition of ARG1 activity through interference of RNA. The unique relationship between Th2 cytokines and arginase levels, particularly in airway inflammation, was not fully established in the human system. The current study was designed to address the impact of IL-13 and IL-4 cytokines on arginase levels/activity in the serum.
Various reports on the association of genetic variants with asthma 15, 16 and response to certain anti-asthmatic drugs 17, 18 in different population suggest that polymorphisms in the arginase gene influence the risk to asthma and atopy 15, 16 . However, the effect of polymorphism on arginase functional activity was not well established. In the present study, two single-nucleotide polymorphisms (SNPs) (rs2781666 and rs60389358) of ARG1 gene, which are located in the promoter region were assessed for the role in the expression of arginase in symptomatic asthma patients and healthy controls.
Material & Methods
Symptomatic randomly selected asthma patients (n=150), attending the Allergy and Pulmonology Clinic, Bhagwan Mahavir Hospital and Research Centre, Hyderabad, India, during the period 2013-2015, were enrolled based on the GINA (Global Initiative for Asthma) guidelines (www.ginasthma.org) after confirmation by lung function test. Age-matched healthy individuals (n=150) without respiratory complications and family history of asthma and allergy were randomly selected from our laboratory, students and general administrative staff and included them as controls for the study. Patients were randomly selected based on the availability at the clinic. The study was approved by the Institutional Ethical Committee. Written and informed consents were obtained from participants to be a part of this observational study. The patients were categorized into groups based on total serum IgE levels and lung function test [forced expiratory volume in one second (FEV 1 )]. Total serum IgE levels were used as surrogate marker for atopy; based on this, the patients were subgrouped into atopic asthmatics who have ≥325 IgE IU/ml (n=74) and non-atopic asthmatics who have <325 IgE IU/ ml (n=76) 19 . The patients were subgrouped based on severity using lung function test (spirometry) according to the GINA guidelines. Those having FEV1 ≥80 per cent of predicted with asymptomatic with peak expiratory flow (PEF) <20 per cent were labelled as intermittent (n=54); FEV 1 80 per cent, symptomatic, with PEF between 20 and 30 per cent as mild persistent (n=37); FEV 1 60-80 per cent as moderate persistent (n=18) and FEV 1 <60 per cent as severe persistent (n=41). Detailed demographic data of the patients characteristics are given in Table I . The mean age of the asthma patients was 34±6 yr and for healthy controls was 41±7 yr with a range of 17-60 and 21-57 yr, respectively. Fifty six asthma patients and 68 healthy controls were male and 94 asthma patients and 82 healthy controls were female. Ten millilitres of peripheral venous blood was collected from each participant for obtaining serum and DNA from cells.
Serum arginase assay: Serum arginase assay was performed in 100 patients and 100 controls using QuantiChrom™ Arginase Assay Kit (Bioassay systems, Hayward, CA, USA) according to the manufacturer's instructions. Briefly, serum samples were incubated in a substrate (arginine) buffer and manganese solution for two hours at 37°C. The reaction was stopped by the addition of urea reagent and incubated for 20 min at room temperature. The final product urea (which indicates the activity of arginase) was read at 520 nm in a spectrophotometer (Bio-Rad, USA). Arginase activity was determined by the formula: optical density (OD) of sample − OD of blank/(OD of standard − OD of water)×10.4 and expressed in units/l. One molar urea solution was used as standard.
Serum cytokine assay: Serum IL-4 and IL-13 levels were assessed in 100 patients and 100 controls by sandwich ELISA using eBioscience (San Diego, CA, USA) reagent kit. Briefly, capture antibodies for IL-4 and IL-13, respectively, were immobilized on 96-well flat plates (cat#3590 Corning USA) and incubated at 4°C overnight. After washing, a blocking buffer was added and incubated for one hour to avoid nonspecific bindings. Standards were serially diluted and 100 µl each of standards and samples were added to the respective wells and incubated at 4°C for two hours. Plates were washed and 100 µl of detection antibody was added to all wells and incubated further for an hour, followed by the addition of avidin tagged to horse radish peroxidase enzyme. Wells were washed before addition of 3,3',5,5'-tetramethylbenzidine (TMB) substrate and the colour change was visualized after stopping the reaction with 2 N H 2 SO 4 . Change in colour was measured at 450 nm in a Bio-Rad microplate spectrophotometer and the OD was observed to be directly proportional to cytokine concentrations. Using MPM 6.0 (Bio-Rad) software, the final concentrations of cytokines were determined.
Genotyping of arginase I (ARG1) gene by restriction fragment length polymorphism (RFLP):
Peripheral blood (2 ml) from 150 participants in each group was collected and the DNA was isolated using a Flexigene DNA Isolation Kit (Qiagen, Hilden, Germany) following the manufacturer's instructions. The concentration (OD at 260 nm) and purity (OD 260/OD 280) were determined using an ND-1000 Spectrophotometer (Thermo Scientific, USA). Genotyping was performed using PCR-RFLP method. PCR was used to amplify 233 bp of ARG1 gene encompassing rs2781666 [(G/T) at −864 position] and rs60389358 [(C/T) at −866 position] loci using sequence-specific primers 5 ' -TCAGGGGCATAGAGGTTGAC-3 ' and 5 ' -TACCATGTGTCCGATGCAGT-3 ' . The primers were designed using Primer3 software 20 . The PCR mixture consisted of MgCl 2 (1.5 mM) , standard concentrations of dNTPs (1 mM) and Taq polymerase (1 U/reaction), specific primers (10 pM) and template DNA (100 ng), and the samples were subjected to 35 cycles. The protocol followed for PCR was pre-denaturation for four minutes at 95°C followed by 35 cycles of denaturation for 45 sec at 94°C, then annealing for 45 sec at 58°C, followed by an extension for 45 sec at 72°C and a final extension at 72°C for seven min after 35 cycles.
The amplified PCR products were subjected to restriction digestion with HpyCH4IV and BsrD1 
Results
Elevated serum arginase activity correlated with severity of asthma: Arginase activity was found to be significantly (P<0.001) elevated (2-folds) in asthma patients compared to healthy controls with a mean±SE of 6.57±0.63 and 3.04±0.33 units/l, respectively (Fig. 1A) . The non- Fig. 1B ). Analysis between arginase activity and severity of the disease indicated a positive correlation. Arginase activity was compared between stratified groups based on severity which was found to be significant (Fig. 1C ). The arginase activity was observed to be 3.34±0.60 units/l in intermittent persistent asthmatics. This was lower but not significantly different from the mild persistent asthmatics (3.70±0.57 units/l) and moderate persistent (8.08±1.36 units/l) groups. However, severe persistent asthma group (13.38±1.56 units/l) significantly varied from intermittent, mild and moderate persistent groups (Fig. 1C ).
Correlation of arginase activity with elevated serum interleukin-13 (IL-13):
Serum cytokine levels of IL-4 and IL-13 were elevated in asthmatics compared to healthy controls with a mean of 13.62±1.92 vs 1.93±0.52 pg/ml for IL-4 and 10.77±1.27 vs 3.54±0.34 pg/ml for IL-13 as shown in Fig. 2A and B, respectively. The differences between the groups were significant (P<0.001) for IL-4 and IL-13 cytokines. Elevated IL-13 levels positively correlated (r=0.25) with elevated arginase activity which was significant (P=0.01) (Fig. 2C) ; however, similar correlation could not be observed with IL-4 (P=0.11) ( Fig. 2D ). Analysis among atopic and non-atopic asthmatics revealed no variation in IL-13; however, IL-4 was high in atopic asthmatics when compared to non-atopics even though the difference was not significant with a mean±SE 12.15±2.44 and 7.6±1.41 pg/ml, respectively ( Fig. 3A and B) . IL-13 and IL-4 levels were increasing with the severity of the disease from intermittent to severe persistent asthma patients ( Fig. 3C and D) . Even though the IL-13 levels were elevated from intermittent persistent to severe persistent asthmatics, significant variation was observed only between intermittent and severe persistent asthma (3.58±1.35 and 18.75±3.33 pg/ml; P<0.001) (Fig. 3C) . The IL-4 levels were observed to be 1.45±0.25 in intermittent persistent asthmatics. The levels were lower than but not significant from mild persistent (8.12±2.17 pg/ml) and moderate persistent asthmatics (9.23±5.09 pg/ml). Significantly (P<0.001) elevated levels of IL-4 were observed in severe persistent group (30.33±5.01 pg/ml) when compared to intermittent persistent (1.45±0.25 pg/ml), mild persistent (8.12±2.17 pg/ml) and moderate persistent (9.23±5.09 pg/ml) asthmatics (Fig. 3D ). co-dominant models of rs2781666 (G/T at −864 position) gene polymorphism were found to be significantly associated with asthma ( Table IIA) . The over-dominant model indicated a higher frequency of GG-TT genotypes in healthy controls with an OR of 2.75 (CI 1.62-4.68, P=0.001), indicating negative association with asthma by conferring the resistance. An association was observed with GT and TT genotypes with OR of 2.58, suggesting that higher risk in dominant model (CI 1.58-4.20, P=0.001) for asthmatics indicates the susceptibility to the disease. The frequency of GT genotypes was significant in asthma with OR of 2.95 (CI 1.71-5.07, P=0.001) indicating association with disease and of TT genotype with OR of 1.71 (CI 0.74-3.92, P=0.001) in co-dominant model. Allelic associations study indicated high frequency of G allele in healthy controls (P=0.01) compared to T allele in asthmatics (P=0.01) (Table IIB) . rs60389358: ARG1 genotype frequency distribution of SNP rs60389358 was not significant between asthma group and healthy controls in any of the models analyzed (Table IIA) . However, significant allele association was observed where C allele was associated with asthmatics (P=0.04) compared to healthy controls in whom T allele was predominant (P=0.04) (Table IIB) .
Haplotypes: Haplotype analysis indicated that C-T haplotype (rs60389358 and rs2781666) frequency was significantly higher in asthmatics (P=0.01) compared to healthy controls (Table III) . In contrast, T-G (rs60389358 and rs2781666) haplotype frequency was high in healthy controls (P=0.02), indicating its negative association with asthma (Table III) .
Linkage disequilibrium analysis between two ARG1 SNPs did not reveal any association (data not shown). Association between elevated arginase activity and SNPs (rs2781666 and rs60389358) was not observed (data not shown). 
Discussion
Extensive studies on different experimental animal models for pathogenesis of asthma suggested that high arginase activity could be one of the reasons for AHR. Our observations on increase in arginase activity in asthma were similar to those in Oakland and Japanese population 7, 11 . Increased arginase activity observed in non-atopics in the present study indicated a possible role in intrinsic asthma. The severity of the disease could be attributed to high serum arginase activity.
This may perhaps lead to increased collagen, mucus production and peroxynitrite concentration resulting in constriction of the airways in asthma 6 . A study by Lara et al 23 demonstrated that increased serum arginase activity and arginine bioavailability correlated strongly to lung function test (pulmonary function tests) in severe asthma group.
Inflammatory role of Th2 cytokines in AHR is well established. We observed elevated levels of IL-4 which was similar to the reports of others 24, 25 ; in addition, a 26 . It has been suggested that IL-4 and IL-13 inflammatory cytokines play a pivotal role in the induction of arginase via cAMP and JAK/STAT6 pathway in asthma 1, 12, 13 .
In vitro rat fibroblast when supplemented with IL-13 and IL-4 showed upregulated arginase activity which was inhibited by glucocorticoids 27 . In our study, a positive correlation between elevated serum IL-13 levels but not IL-4 with arginase activity was observed in asthma patients. Yang et al 14 demonstrated in mice that IL-13-induced AHR was attenuated by inhibition of ARG1 activity and it alone may be sufficient to induce arginase in STAT6-dependent manner. As we observed positive correlation of the arginase activity with levels of IL-13, we hypothesize that this may lead to hyperresponsiveness in asthma in our patients.
With increase in serum arginase levels of asthmatics, further analysis of genetic variation in the promoter region of arginase gene (ARG1) assessed showed a significant association of ARG1 polymorphism at rs2781666 (G/T) position with susceptibility of asthma. Our results suggest that at rs2781666 homozygous GG genotype and allele G may offer protection and heterozygous GT genotype and T allele may confer susceptibility to asthma.
Although we did not observe any significant ARG1 genotype association of rs60389358 SNP with asthma, the alleles were associated where C allele towards susceptibility and T in protection from asthma. Duan et al 18 studied arginase haplotypes using four different SNPs of arginase, of which rs60389358 SNP was found to be associated with altered bronchodilator response. Our haplotype analysis revealed that C-T haplotype (rs60389358 and rs2781666) might be susceptible to asthma whereas haplotype T-G (rs60389358 and rs2781666) might offer resistance to asthma. No correlation was observed between genotypes of rs2781666 and rs60389358 and elevated levels of arginase in the serum of asthma patients. The sample size was small between genotypes which might not be sufficient to correlate with arginase activity in the present study.
The incidence of asthma globally increased at faster rate and anticipated to reach 443 million by 2025 28 . Asthma prevalence is soaring up in developing countries like India with huge economical burden 29 . Since asthma is a complex condition with the involvement of multiple mechanisms, there is a need for new therapeutic interventions. Animal models of asthma demonstrated that arginase is a key player in pathogenesis and its inhibition may lead to the reduction of AHR 2,10,14,30 . There are a few studies that showed the association of arginase with asthma in humans 7, 11 .
Our findings demonstrated that elevated serum arginase activity and IL-13 levels and ARG1 rs2781666 G/T genotype might increase the risk of asthma. Therefore, the present study strengthens the argument that inhibition of arginase or IL-13 (which may have an indirect effect on arginase production) may have therapeutic potential in the treatment of asthma. A weak positive association was observed between IL-13 and arginase in a small portion of asthma patients; it could be due to low sample size which was a limitation of the study. Further, functional studies on the susceptible genotype/haplotype in ARG1 gene might provide an insight into the role and use of ARG1 gene as a genetic biomarker for asthma. It is well established that high IgE levels lead to manifestation of atopic asthma 31 . In this study that non-atopics did not have high IgE levels but had high arginase activity which correlated well with high IL-13 levels. The observations indicate the role of arginase in non-atopic asthma. Further studies are required on IL-13 receptor and its role on arginase induction to confirm this hypothesis. 
